Abstract Body

Background

Dolutegravir plus lamivudine (DTG+3TC) is recommended for ART-naïve and virologically
suppressed people with HIV (PWH). Evidence on its effectiveness in treatment-experienced
individuals with prior virological failure or resistance, particularly in low- and middle-income
countries (LMICs), remains limited. We assessed real-world outcomes of DTG+3TC in
Thailand’s National AIDS Program (NAP).

Methods

We conducted a retrospective cohort study using de-identified NAP data. ART-experienced PWH
who switched to DTG+3TC between Jan 1, 2020, and Dec 31, 2023, were included if aged ≥15
years with ≥6 months follow-up and available HIV-RNA data. Suspected 3TC resistance was
defined by prior resistance, virological failure (VF;VL ≥1000 copies/mL) on FTC/3TC, or use
of boosted PI after NNRTI/NRTI failure. The primary outcome was virological
suppression (VL <50 copies/mL) at 12 months; secondary outcomes included VF and predictors
of VF.

Results

Of 12,379 PWH who initiated DTG+3TC, 6,460 were eligible. Median age was 52.9 years,
60.5% were male, and median ART duration was 10 years. At baseline, 299 (4.6%) had
HIV VL> 50 copies/mL. At 12 months, 97.3% of participants suppressed at switch remained
suppressed, with VF in 0.9%. Among viremic individuals, 78.2% achieved suppression while
6.1% developed VF. At 24 months, 96.9% of suppressed participants had VL<50 copies/mL
(0.9% VF), compared with 79.4% suppression and 5.2% VF among viremic individuals. Overall,
among those with prior 3TC resistance or treatment failure, VF was higher in viremic
participants (23.9%) than in those suppressed at switch (6.1%, p<0.001). Viremic participants
without prior resistance or failure had lower VF rates (9.4%) than those with prior failure
(28.6%, p<0.001). In multivariable analysis, predictors of VF included baseline CD4 <350
cells/mm³ (aHR 1.84, 95% CI 1.12–2.39), prior VL rebound (2.39, 1.62–3.53), persistent pre-
switch viraemia (4.32, 1.88–9.94), recent resistance/failure <3 years (2.03, 1.03–4.00), and
resistance/failure 3–<10 years (1.86, 1.05–3.29). Resistance/failure ≥10 years was not
significantly associated with VF.

Conclusions

DTG+3TC was highly effective and durable for maintaining suppression in ART-experienced
PWH who were virologically suppressed at switch, including those with historical 3TC
resistance. Outcomes were markedly poorer in PWH with ongoing viremia or recent failure.
Careful selection based on virological status, ART history, and immune recovery is essential for
safe and durable DTG+3TC use in LMIC programs.